Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 1/20 | 0.65 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.63 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.63 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.54 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30622701 | 1.00 | HTT (0.65) | HTTLMNAMAPK1RAB9ATAS1R3 | |
| Hydrochloric Acid SCHEMBL6510141 | 0.98 | HTT (0.63) | HTTLMNAMAPK1RAB9ATAS1R3 | |
| SCHEMBL30622691 | 0.87 | CA1 (0.54) | HTTLMNAMAPK1RAB9ATAS1R3 | |
| SCHEMBL15024200 | 0.87 | CA1 (0.54) | HTTLMNAMAPK1RAB9ATAS1R3 | |
| SCHEMBL7984450 | 0.85 | LMNA (0.67) | HTTLMNAMAPK1RAB9ATAS1R3 | |
| SCHEMBL29412632 | 0.84 | CYP1A2 (0.63) | MAPK1RAB9ACA1CA2MEN1 | |
| SCHEMBL2446906 | 0.84 | CYP1A2 (0.63) | MAPK1RAB9ACA1CA2MEN1 | |
| SCHEMBL6578700 | 0.84 | KCNQ3 (0.60) | HTTLMNAMAPK1RAB9ATAS1R3 | |
| SCHEMBL21974593 | 0.83 | KCNQ3 (0.58) | HTTLMNAMAPK1RAB9ATAS1R3 | |
| SCHEMBL6580973 | 0.82 | KCNQ3 (0.45) | HTTLMNAMAPK1RAB9ATAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346588-A1 | IMIDAZOPYRIDINE AND OXAZOLOPYRIDINE DERIVATIVES AND ANALOGS THEREOF, METHODS OF PREPARATION THEREOF, METHODS OF HIF-1/2A PATHWAY INHIBITION, AND INDUCTION OF FERROPTOSIS | KUDA THERAPEUTICS INC (US) | 2025-11-13 | — | — | US | disclosed |
| EP-4531838-A1 | IMIDAZOPYRIDINE AND OXAZOLOPYRIDINE DERIVATIVES AND ANALOGS THEREOF, METHODS OF PREPARATION THEREOF, METHODS OF HIF-1/2A PATHWAY INHIBITION, AND INDUCTION OF FERROPTOSIS | Kuda Therapeutics, Inc. (US) | 2025-04-09 | — | — | EP | disclosed |
| WO-2023234970-A1 | IMIDAZOPYRIDINE AND OXAZOLOPYRIDINE DERIVATIVES AND ANALOGS THEREOF, METHODS OF PREPARATION THEREOF, METHODS OF HIF-1/2A PATHWAY INHIBITION, AND INDUCTION OF FERROPTOSIS | KUDA Therapeutics, Inc. (US) | 2023-12-07 | — | — | WO | disclosed |
| US-11584726-B2 | Amino alcohol derivative, pharmaceutical composition and application thereof | BEIJING FORELAND PHARMA CO., LTD. (CN) | 2023-02-21 | — | — | US | disclosed |
| US-11447482-B1 | Imidazopyridine and oxazolopyridine derivatives and analogs thereof, methods of preparation thereof, methods of HIF-2A pathway inhibition, and induction of ferroptosis | KUDA Therapeutics, Inc. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20220281862-A1 | Imidazopyridine and Oxazolopyridine Derivatives and Analogs Thereof, Methods of Preparation Thereof, Methods of HIF-2A Pathway Inhibition, and Induction of Ferroptosis | KUDA Therapeutics, Inc. | 2022-09-08 | — | — | US | disclosed |
| US-20220281862-A1 | Imidazopyridine and Oxazolopyridine Derivatives and Analogs Thereof, Methods of Preparation Thereof, Methods of HIF-2A Pathway Inhibition, and Induction of Ferroptosis | KUDA Therapeutics, Inc. | 2022-09-08 | — | — | US | disclosed |
| US-20210347745-A1 | AMINO ALCOHOL DERIVATIVE, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | BEIJING FORELAND PHARMA CO., LTD. (CN) | 2021-11-11 | — | — | US | disclosed |
| EP-3647309-A1 | AMINO ALCOHOL DERIVATIVE, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | Beijing Foreland Pharma Co., Ltd. (CN) | 2020-05-06 | — | — | EP | disclosed |
| WO-2005082866-A2 | SUBSTITUTED 1, 2, 4- TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LIMITED (GB) | 2005-09-09 | — | — | WO | disclosed |
| EP-1070708-B1 | Triazole derivatives | HOFFMANN LA ROCHE (CH) | 2004-01-14 | — | — | EP | disclosed |
| US-6265426-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | HOFFMANN-LA ROCHE INC. | 2001-07-24 | — | — | US | disclosed |
| EP-1070708-A1 | Triazole and imidazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2001-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210347745-A1 | AMINO ALCOHOL DERIVATIVE, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | SSB, HLA-DRB1, LCP2 | HTT 2576/4885LMNA 438/4885MAPK1 2355/4885 |
| US-20250346588-A1 | IMIDAZOPYRIDINE AND OXAZOLOPYRIDINE DERIVATIVES AND ANALOGS THEREOF, METHODS OF PREPARATION THEREOF, METHODS OF HIF-1/2A PATHWAY INHIBITION, AND INDUCTION OF FERROPTOSIS | HIF1AN, HIF1A, EGLN2 | HTT 1194/4885LMNA 3699/4885MAPK1 815/4885 |
| US-11447482-B1 | Imidazopyridine and oxazolopyridine derivatives and analogs thereof, methods of preparation thereof, methods of HIF-2A pathway inhibition, and induction of ferroptosis | HIF1AN, HIF1A, EGLN2 | HTT 2758/4885LMNA 3402/4885MAPK1 1296/4885 |
| US-20220281862-A1 | Imidazopyridine and Oxazolopyridine Derivatives and Analogs Thereof, Methods of Preparation Thereof, Methods of HIF-2A Pathway Inhibition, and Induction of Ferroptosis | HIF1AN, HIF1A, EGLN2 | HTT 2758/4885LMNA 3402/4885MAPK1 1296/4885 |
| US-11584726-B2 | Amino alcohol derivative, pharmaceutical composition and application thereof | SSB, HLA-DRB1, LCP2 | HTT 2576/4885LMNA 438/4885MAPK1 2355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.